| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 262 |
| 1 | PREDNISONE | 240 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 236 |
| 3 | TACROLIMUS OINTMENT 0.1% | 236 |
| 4 | MYCOPHENOLATE MOFETIL | 190 |
| 5 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 190 |
| 6 | MYCOPHENOLIC ACID | 89 |
| 7 | RITUXIMAB | 83 |
| 8 | MYCOPHENILIC ACID | 78 |
| 9 | METHOTREXATE SODIUM | 65 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NELARABINE | 9 | 0.0092 |
| 1 | ANTI-THYMOCYTE GLOBULIN (RABBIT) | 37 | 0.0045 |
| 2 | MYCOPHENILIC ACID | 78 | 0.0037 |
| 3 | MYCOPHENOLIC ACID | 89 | 0.0027 |
| 4 | TREOSULFAN | 6 | 0.0022 |
| 5 | TACROLIMUS OINTMENT 0.1% | 236 | 0.0019 |
| 6 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 236 | 0.0018 |
| 7 | TILDRAKIZUMAB-ASMN | 4 | 0.0017 |
| 8 | TACROLIMUS | 262 | 0.0016 |
| 9 | BASILIXIMAB | 17 | 0.0014 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 320 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 136 |
| 2 | Antimetabolite Immunosuppressant [EPC] | 78 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 61 |
| 4 | Alkylating Drug [EPC] | 42 |
| 5 | Kinase Inhibitor [EPC] | 39 |
| 6 | Immunoglobulin G [EPC] | 37 |
| 7 | Tumor Necrosis Factor Blocker [EPC] | 32 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 27 |
| 9 | mTOR Inhibitor Immunosuppressant [EPC] | 26 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antimetabolite Immunosuppressant [EPC] | 78 | 0.0037 |
| 1 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 2 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 3 | 0.0009 |
| 3 | CCR5 Co-receptor Antagonist [EPC] | 2 | 0.0009 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 5 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 6 | Human Immunoglobulin G [EPC] | 10 | 0.0005 |
| 7 | CD52-directed Cytolytic Antibody [EPC] | 9 | 0.0005 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 136 | 0.0004 |
| 9 | Sulfone [EPC] | 4 | 0.0004 |